- Home
- LNZA vs SAVA Comparison
LNZA vs SAVA Comparison
Compare LNZA & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- SAVA
- Stock Information
- Founded
- LNZA 2005
- SAVA 1998
- Country
- LNZA United States
- SAVA United States
- Employees
- LNZA N/A
- SAVA N/A
- Industry
- LNZA Major Chemicals
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- LNZA Industrials
- SAVA Health Care
- Exchange
- LNZA Nasdaq
- SAVA Nasdaq
- Market Cap
- LNZA 65.7M
- SAVA 70.5M
- IPO Year
- LNZA N/A
- SAVA N/A
- Fundamental
- Price
- LNZA $0.28
- SAVA $1.98
- Analyst Decision
- LNZA Hold
- SAVA Buy
- Analyst Count
- LNZA 2
- SAVA 2
- Target Price
- LNZA $2.00
- SAVA $54.50
- AVG Volume (30 Days)
- LNZA 2.3M
- SAVA 1.1M
- Earning Date
- LNZA 08-07-2025
- SAVA 08-07-2025
- Dividend Yield
- LNZA N/A
- SAVA N/A
- EPS Growth
- LNZA N/A
- SAVA N/A
- EPS
- LNZA N/A
- SAVA N/A
- Revenue
- LNZA $48,831,000.00
- SAVA N/A
- Revenue This Year
- LNZA $58.17
- SAVA N/A
- Revenue Next Year
- LNZA $10.92
- SAVA N/A
- P/E Ratio
- LNZA N/A
- SAVA N/A
- Revenue Growth
- LNZA N/A
- SAVA N/A
- 52 Week Low
- LNZA $0.14
- SAVA $1.15
- 52 Week High
- LNZA $2.74
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- LNZA 50.45
- SAVA 51.34
- Support Level
- LNZA $0.25
- SAVA $1.91
- Resistance Level
- LNZA $0.30
- SAVA $2.05
- Average True Range (ATR)
- LNZA 0.04
- SAVA 0.10
- MACD
- LNZA -0.00
- SAVA -0.00
- Stochastic Oscillator
- LNZA 37.85
- SAVA 54.93
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.